Electronic Supplementary Material (ESI) for Organic & Biomolecular Chemistry. This journal is © The Royal Society of Chemistry 2024

Electronic Supplementary Information

Green light-mediated dual eosin Y/Pd^{II}-catalyzed C(sp²)–H arylation of N–H unprotected 2-arylquinazolinone

Shuvam Mondal,^{*a*} and Ranjan Jana^{**a*,*b*}

^aOrganic and Medicinal Chemistry Division, CSIR-Indian Institute of Chemical Biology

4 Raja S. C. Mullick Road, Jadavpur, Kolkata-700032, West Bengal, India

^bAcademy of Scientific and Innovative Research (AcSIR), Ghaziabad-201 002, Uttar Pradesh, India E-mail: rjana@iicb.res.in

Table of Contents

General information	3
Preparation of starting materials	3
Representative procedures for the main reaction	4
Mechanistic studies	4-8
Spectral data	9-26
Nuisance effect and C–H arylation	27-28
Crystal structure	
References	30
¹ H, ¹³ C and ¹⁹ F NMR spectra	

General Information:

All manipulations with air-sensitive reagents were carried out under a dry nitrogen atmosphere. Unless otherwise stated, all commercial reagents were used without additional purification. Solvents were dried using standard methods and distilled before use. TLC was performed on silica gel plates (Merck silica gel 60, f254), and the spots were visualized with UV light (254 and 365 nm). ¹H NMR was recorded at 400 MHz (JEOL-JNM-ECZ400S/L1) and 600 MHz (Bruker-Avance 600) frequency and ¹³C NMR spectra were recorded at 100 MHz (JEOL-JNM-ECZ400S/L1) and 150 MHz (Bruker-Avance) frequency in CDCl₃ solvent using TMS as the internal standard. ¹⁹F NMR was recorded at 376 MHz frequency (JEOL-JNM-ECZ400S/L1). Chemical shifts were measured in parts per million (ppm) referenced to 0.0 ppm for tetramethylsilane. The following abbreviations were used to explain multiplicities: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br. = broad. Coupling constants, *J* were reported in Hertz unit (Hz). HRMS (m/z) were measured using ESI techniques Q-Tof Micro mass spectrometer respectively. Crystals were grown in dichloromethane-hexane and crystal data was recorded in Bruker Kappa Apex-2 (CCD Area Detector) or Bruker D8 Venture (Photon-III detector). Kessil PR160-456 nm, Kessil PR160L-440 nm and PR160L-525 nm were used as a source of blue LEDs and green LEDs light for the reaction.

Synthesis of the starting materials:

The starting material substituted anthranilamide,¹ 2-phenylquinazolin-4(3H)-one,^{2, 3} and Isoquinolin-1(2*H*)-one⁴ substrates were prepared using literature-reported methods. Aryl diazonium salts⁵ were prepared on a 5 mmol scale according to the literature.

Synthesis of the Aryl triflate Diazonium Salt:



Figure 1: Preparation of 4-aminophenyl trifluoromethanesulfonate.

4-Nitro phenyl trifluoromethanesulfonate (A) was prepared as per the reported procedure.⁶ Then 4aminophenyl trifluoromethanesulfonate was synthesized from (A) with a modified process.⁷

Preparation of Fe Nanoparticles and Nitro reduction⁷: In a 500 mL round bottom flask, ferrous sulphatehepta-hydrate [FeSO₄, 7H₂O] (3.4 g, 12 mmol) and citric acid (220 mg, 1 mmol) were taken in distilled water (250 mL) and stirring to dissolve the solid. Then, Sodium borohydride (NaBH₄) (800 mg, 20 mmol) was added to it portion-wise, and vigorous stirring was continued for 5 minutes. Thereafter, the solution was settled down and the water layer was decanted. The residual black solid material of Fe nanoparticles was further washed with distilled water two times to be ready for use in nitro reduction. The nitro compound **(A)** (4 mmol) was added to these Fe nanoparticles in distilled water (10 mL) in the same pot under constant stirring for 24 h at room temperature under argon atmosphere. The reaction mixture is filtered through celite pad and washed with ethyl acetate thoroughly. Then collected filtrate is poured into a separatory funnel to eliminate the water part. The

ethyl acetate part is concentrated under reduced pressure and product (B) is isolated by column chromatography. (Yield 83%).



Figure 2: Diazonium salt Preparation.

Aniline **(B)** (2.5 mmol) was taken in a 50 mL round bottom flask and cooled in an ice bath, and tetrafluoroboric acid solution (48 wt % in H_2O , 0.85 mL) was added at 0 °C. To the precipitate, 1 mL of distilled water was added. Then, Sodium nitrite (173 mg, 2.5 mmol) in distilled water (2 mL) was added dropwise to the reaction mixture and allowed to stir for 50 min at 0 °C. A thick precipitate was formed and collected by filtration. The precipitate was washed with diethyl ether (10 mL) three times. The resulting precipitate was recrystallized with acetonitrile/diethyl ether to give the desired aryldiazonium tetrafluoroborate as a brown solid.

General procedure for dual palladium-photoredox catalyzed C–H arylation of quinazoline scaffold:

To an oven-dried Schlenk tube equipped with a magnetic stir bar, 2-phenyl quinazoline derivative (0.3 mmol, 1 equiv), freshly prepared aryldiazonium salt (1.2 mmol, 4 equiv), $Pd(OAc)_2$ (10 mol%, 6.7 mg), Eosin Y (1 mol%, 2.1 mg), and MeOH (4.5 mL), were sequentially added. Then the tube was freezed in liquid N₂, degassed by the freeze-pump-thaw procedure refilled with argon gas. This freeze-pump-thaw procedure was parformed three times. Then the schlenk tube was placed on a magnetic stirrer with Kessil Green LED light (40 W) kept about 4 cm away from it. After 30 h, the solvent was evaporated under reduced pressure, and work up with DCM-water. Then, the residue was purified by silica gel column chromatography (eluting with Ethyl Acetate/Hexane) to isolate the desired product. During the photoirradiation, the reaction temperature was probed to be in the range of 33 °C - 35 °C.

Mechanistic Study:

Intermolecular Kinetic Experiment:

A mixture of 2-phenylquinazolin-4(3H)-one (0.15 mmol), d_5 -2-phenylquinazolin-4(3H)-one (0.15 mmol), freshly prepared aryldiazonium salt (1.2 mmol, 4 equiv), Pd(OAc)₂ (10 mol%, 6.7 mg), Eosin Y (1 mol%, 2.1 mg), and MeOH (4.5 mL), were taken in an oven-dried schlenk tube equipped with a magnetic stir bar. Then the tube was freezed in liquid N₂ and degassed by the freeze-pump-thaw procedure refilling with argon gas (three times). Then the reaction tube was placed on a magnetic stirrer with Kessil Green LED light (40 W) kept about 4 cm away from it and irradiated at room temperature with constant stirring for 12 h. Thereafter, the solvent was evaporated under reduced pressure and worked up with DCM-water. Then, the residue was purified by silica gel column chromatography (eluting with Ethyl Acetate/Hexane) to isolate the desired product. The K_H/K_D value was determined by ¹H NMR analysis.



Figure 3: Primary kinetic isotope effect experiment.





Free radical-trapping experiment for arylation:

2-phenylquinazolin-4(3H)-one **1a** (0.3 mmol), phenyl diazonium trifluoroborate **2e** (1.2 mmol), Eosin Y (1.0 mol%), $Pd(OAc)_2$ (10 mol%) and, TEMPO (79.5 mg, 0.5 mmol) were taken in MeOH (4.5 mL) in an oven-dried Schlenk tube and after performing freeze-thaw-pump it was placed magnetic stirring, irradiated with 40 W green LED at room temperature for 30 h. The reaction was concentrated under reduced pressure and worked up with DCM-Water. Phenyl-TEMPO adduct was detected by HRMS which confirms the presence of free radical formation during the reaction.

HRMS of TEMPO-adduct product C₁₅H₂₃NO [M+H]⁺ : Exact Mass: 234.1858; found: 234.1853.







Figure 6: HRMS analysis of the reaction mixture.



Figure 7: Arylation reaction of 2-(o-tolyl)quinazolin-4(3H)-one (9).



HRMS of arylated product $C_{21}H_{15}BrN_2O [M+H]^+$: Exact Mass: 391.0446; found: 391.0457.

Figure 8: MS analysis of the reaction mixture of 2-(o-tolyl)quinazolin-4(3H)-one (9).

Plausible mechanism for C–H arylation under thermal condition (no light irradiation) and green light irradiation in the absence of an photocatalyst:



An anticipated mechanism is drawn here for the aryl reaction occurring in thermal conditions and light irradiation without any photocatalyst. Certain thermal or photonic energy may induce aryl radical formation ^{8, 9} in methanol, which coupled with the Pd-complex **(A)** and results in the formation of either cationic Pd(III) [via 1e transfer] or Pd(IV) [via 2e transfer] complex. Again, the presence of excess aryl diazonium salt may be considered to be involved in electronic transfer. Thereafter, reductive elimination from high valent Pd complex **(B)** afforded product **(C)**.

Spectral data



Aryl triflate diazonium salt (C).

¹H NMR (400 MHz, Acetone-*d*₆) δ 9.18 – 9.11 (m, 2H), 8.28 – 8.23 (m, 2H).

¹⁹F NMR (376 MHz, Acetone-*d*₆) δ -73.63, -150.87, -150.92.

¹³C NMR (100 MHz, Acetone- d_6) δ 157.6, 137.2, 126.2, 119.5 (q, *J* = 318 Hz), 117.3.



3,4-difluoro phenyl diazonium salt (2u):

¹H NMR (400 MHz, Acetone-*d*₆) δ 8.96 (ddd, *J* = 9.0, 6.6, 2.6 Hz, 1H), 8.90 –8.85 (m, 1H), 8.11 (td, *J* = 9.5, 7.5 Hz, 1H).

¹⁹F NMR (376 MHz, Acetone- d_6) δ -111.49 – -111.54 (m, 1F), -129.52 (dt, *J* = 19.4, 8.2 Hz, 1F), -150.65 (s, 1F), -150.70 (s, 3F).

¹³C NMR (100 MHz, Acetone- d_6) δ 159.7 (dd, J = 270.8, 11.9 Hz), 151.0 (dd, J = 257.3, 14.4 Hz), 134.1 (dd, J = 10.6, 3.9 Hz), 123.9 (dd, J = 25.2, 3.7 Hz), 122.3 (d, J = 21.1 Hz), 112.5 – 112.4 (m).



3-fluoro-4-methoxy phenyl diazonium salt (2u'):

¹H NMR (400 MHz, Acetone- d_6) δ 8.77 (ddd, J = 9.3, 2.6, 1.4 Hz, 1H), 8.63 (dd, J = 9.7, 2.6 Hz, 1H), 7.81 (dd, J = 9.3, 7.9 Hz, 1H), 4.27 (s, 3H).

¹⁹F NMR (376 MHz, Acetone- d_6) δ -128.21 (t, J = 9.4 Hz, 1H), -150.77 (s, 1H), -150.82 (s, 3H).

¹³C NMR (100 MHz, Acetone- d_6) δ 160.7 (d, J = 10.0 Hz), 151.8 (d, J = 254.8 Hz), 135.0 (d, J = 2.8 Hz), 120.5 (d, J = 26.1 Hz), 117.1 (d, J = 2.5 Hz), 103.8 (d, J = 10.8 Hz), 58.8.



2-(4'-chloro-[1,1'-biphenyl]-2-yl)quinazolin-4(3H)-one (3aa): Column chromatography (SiO₂, eluting with 5:1 hexane/ethyl acetate) afforded the desired product as a white solid (80 mg, 80%).

¹H NMR (400 MHz, CDCl₃) δ 9.89 (s, 1H), 8.17 (d, *J* = 8.0 Hz, 1H), 7.85 – 7.73 (m, 3H), 7.58 (td, *J* = 7.6, 1.3 Hz, 1H), 7.51 (dd, *J* = 7.7, 1.2 Hz, 2H), 7.46 (td, *J* = 7.3, 1.2 Hz, 1H), 7.27 – 7.17 (m, 4H).

 ^{13}C NMR (100 MHz, CDCl_3) δ 162.5, 153.6, 149.2, 139.5, 137.9, 134.9, 134.1, 132.8, 131.1, 130.9, 130.5, 130.4, 128.9, 128.3, 127.9, 127.2, 126.4, 120.7.

HRMS (ESI, m/z) calcd. for $C_{20}H_{14}CIN_2O [M+H]^+$: 333.0795; found: 333.0783.



2-(4'-bromo-[1,1'-biphenyl]-2-yl)quinazolin-4(3H)-one (3ab):

Column chromatography (SiO₂, eluting with 5:1 hexane/ethyl acetate) afforded the desired product as a brown solid (87.1 mg, 77%).

¹H NMR (400 MHz, CDCl₃) δ 9.45 (s, 1H), 8.19 (dd, *J* = 8.0, 1.5 Hz, 1H), 7.84 (dd, *J* = 7.6, 1.5 Hz, 1H), 7.82 – 7.74 (m, 2H), 7.60 (td, *J* = 7.5, 1.5 Hz, 1H), 7.55 – 7.49 (m, 2H), 7.49 – 7.44 (m, 1H), 7.42 – 7.37 (m, 2H), 7.23 – 7.18 (m, 2H).

¹³C NMR (100 MHz, CDCl₃) δ 161.9, 153.4, 149.1, 139.4, 138.3, 135.0, 132.7, 132.1, 131.3, 130.9, 130.6, 130.6, 128.5, 128.0, 127.3, 126.6, 122.6, 120.8.

HRMS (ESI, m/z) calcd. for C₂₀H₁₄BrN₂O [M+H]⁺ : 377.0290; found: 377.0274.



2-(4'-iodo-[1,1'-biphenyl]-2-yl)quinazolin-4(3H)-one (3ac):

Column chromatography (SiO₂, eluting with 5:1 hexane/ethyl acetate) afforded the desired product as a brown solid (44.5 mg, 35%).

¹H NMR (400 MHz, CDCl₃) δ 9.11 (s, 1H), 8.20 (dd, *J* = 7.6, 1.3 Hz, 1H), 7.85 (dd, *J* = 7.6, 1.5 Hz, 1H), 7.83 - 7.74 (m, 2H), 7.66 - 7.61 (m, 2H), 7.61 - 7.47 (m, 3H), 7.46 (dd, *J* = 7.6, 1.4 Hz, 1H), 7.11 - 7.05 (m, 2H).

 ^{13}C NMR (100 MHz, CDCl₃) δ 161.8, 153.4, 149.1, 139.5, 138.8, 138.1, 135.0, 132.7, 131.3, 130.9, 130.8, 130.6, 128.5, 128.0, 127.3, 126.6, 120.8, 94.3.

HRMS (ESI, m/z) calcd. for $C_{20}H_{14}IN_2O [M+H]^+$: 425.0151; found: 425.0158.



2'-(4-oxo-3,4-dihydroquinazolin-2-yl)-[1,1'-biphenyl]-4-yl trifluoromethanesulfonate (3ad):

Column chromatography (SiO₂, eluting with 5:1 hexane/ethyl acetate) afforded the desired product as a brown solid (73.6 mg, 55%).

¹H NMR (400 MHz, CDCl₃) δ 10.62 (s, 1H), 8.15 (dd, *J* = 8.0, 1.5 Hz, 1H), 7.82 (dd, *J* = 7.6, 1.5 Hz, 1H), 7.80 –7.75 (m, 1H), 7.66 (d, *J* = 8.2 Hz, 1H), 7.62 (dd, *J* = 7.5, 1.5 Hz, 1H), 7.56 (td, *J* = 7.5, 1.4 Hz, 1H), 7.52 – 7.46 (m, 2H), 7.42 – 7.37 (m, 2H), 7.15 – 7.10 (m, 2H).

 ^{19}F NMR (376 MHz, CDCl₃) δ -72.69.

 ^{13}C NMR (100 MHz, CDCl₃) δ 162.8, 153.2, 149.1, 140.3, 139.2, 135.1, 133.0, 131.2, 131.0, 130.9, 130.3, 128.7, 128.0, 127.3, 126.4, 121.4, 120.5, δ 118.8 (q, J = 319.2 Hz).

HRMS (ESI, m/z) calcd. for $C_{21}H_{14}F_3N_2O_4S$ [M+H]⁺ : 447.0626 ; found: 447.0624.



2-([1,1'-biphenyl]-2-yl)quinazolin-4(3H)-one (3ae):

Column chromatography (SiO₂, eluting with 5:1 hexane/ethyl acetate) afforded the desired product as a white solid (35.7 mg, 40%).

¹H NMR (600 MHz, CDCl₃) δ 9.16 (s, 1H), 8.17 (d, *J* = 7.8 Hz, 1H), 7.89 (d, *J* = 7.5 Hz, 1H), 7.82 – 7.76 (m, 2H), 7.59 (t, *J* = 7.5 Hz, 1H), 7.54 – 7.46 (m, 3H), 7.34 – 7.31 (m, 2H), 7.27-7.30 (m, 3H).

¹³C NMR (100 MHz, CDCl₃) δ 161.7, 153.7, 149.1, 140.6, 139.2, 134.9, 132.6, 131.2, 131.0, 130.6, 129.0, 128.4, 128.2, 127.9, 127.2, 126.6, 120.8.

HRMS (ESI, m/z) calcd. for $C_{20}H_{15}N_2O$ [M+H]⁺ : 299.1184; found: 299.1177.



2-(4'-methyl-[1,1'-biphenyl]-2-yl)quinazolin-4(3H)-one (3af):

Column chromatography (SiO₂, eluting with 5:1 hexane/ethyl acetate) afforded the desired product as a white solid (57 mg, 61%).

¹H NMR (600 MHz, CDCl₃) δ 8.76 (s, 1H), 8.19 (dd, *J* = 8.0, 1.5 Hz, 1H), 7.91 (dd, *J* = 7.6, 1.4 Hz, 1H), 7.83 (d, *J* = 8.1 Hz, 1H), 7.81 – 7.77 (m, 1H), 7.58 (td, *J* = 7.6, 1.4 Hz, 1H), 7.52 – 7.42 (m, 3H), 7.23 (d, *J* = 8.0 Hz, 2H), 7.13 (d, *J* = 7.8 Hz, 2H), 2.33 (s, 3H).

¹³C NMR (100 MHz, CDCl₃) δ 161.6, 153.8, 149.2, 140.5, 138.3, 136.1, 134.8, 132.6, 131.1, 131.0, 130.6, 129.8, 128.9, 128.0, 127.1, 126.6, 120.8, 21.3.

HRMS (ESI, m/z) calcd. for $C_{21}H_{17}N_2O$ [M+H]⁺ : 313.1341; found: 313.1327.



2-(4'-methoxy-[1,1'-biphenyl]-2-yl)quinazolin-4(3H)-one (3ag):

Column chromatography (SiO₂, eluting with 5:1 hexane/ethyl acetate) afforded the desired product as a brown solid (69.8 mg, 71%).

¹H NMR (400 MHz, CDCl₃) δ 9.04 (s, 1H), 8.19 (d, *J* = 7.8 Hz, 1H), 7.87 (dd, *J* = 8.0, 1.3 Hz, 1H), 7.86 – 7.74 (m, 2H), 7.61 – 7.51 (m, 1H), 7.54 – 7.41 (m, 3H), 7.31 – 7.19 (m, 2H), 6.87 – 6.75 (m, 2H), 3.76 (s, 3H).

¹³C NMR (100 MHz, CDCl₃) δ 161.7, 159.6, 153.9, 149.3, 140.1, 134.8, 132.5, 131.2, 131.1, 131.0, 130.6, 130.2, 128.0, 127.7, 127.1, 126.6, 120.9, 114.5, 55.3.

HRMS (ESI, m/z) calcd. for C₂₁H₁₇N₂O₂ [M+H]⁺ : 329.1290; found: 329.1275.



2-(4'-(trifluoromethyl)-[1,1'-biphenyl]-2-yl)quinazolin-4(3H)-one (3ah):

Column chromatography (SiO₂, eluting with 5:1 hexane/ethyl acetate) afforded the desired product as a brown solid (95.5 mg, 87%).

¹H NMR (600 MHz, CDCl₃) δ 10.22 (s, 1H), 8.16 (dd, *J* = 7.9, 1.5 Hz, 1H), 7.82 - 7.77 (m, 2H), 7.71 (d, *J* = 8.1 Hz, 1H), 7.62 (td, *J* = 7.6, 1.4 Hz, 1H), 7.54 (td, *J* = 7.6, 1.3 Hz, 1H), 7.52 - 7.46 (m, 4H), 7.44 (d, *J* = 8.2 Hz, 2H).

 ^{19}F NMR (376 MHz, CDCl₃) δ -62.46.

¹³C NMR (100 MHz, CDCl₃) δ 162.5, 153.3, 149.1, 143.3, 139.5, 135.1, 133.0, 131.2, 131.0, 130.5, 130.0 (q, J = 32 Hz), 129.5, 128.8, 124.1 (q, J = 271 Hz), 128.0, 127.3, 126.5, 125.6 (q, J = 4.0 Hz), 120.7.

HRMS (ESI, m/z) calcd. for $C_{21}H_{14}F_3N_2O [M+H]^+$: 367.1058; found: 367.1043.



2-(4'-(trifluoromethoxy)-[1,1'-biphenyl]-2-yl)quinazolin-4(3H)-one (3ai):

Column chromatography (SiO₂, eluting with 5:1 hexane/ethyl acetate) afforded the desired product as a brown solid (98.5 mg, 86%).

¹H NMR (400 MHz, CDCl₃) δ 9.85 (s, 1H), 8.18 (dd, *J* = 7.9, 1.5 Hz, 1H), 7.84 – 7.76 (m, 2H), 7.72 (dd, *J* = 8.2, 1.3 Hz, 1H), 7.61 (td, *J* = 7.6, 1.5 Hz, 1H), 7.56 – 7.46 (m, 3H), 7.38 – 7.33 (m, 2H), 7.13 – 7.07 (m, 2H).

 ^{19}F NMR NMR (376 MHz, CDCl₃) δ -57.71.

¹³C NMR (100 MHz, CDCl₃) δ 162.2, 153.4, 149.1, 149.0, 139.4, 138.2, 135.0, 132.9, 131.2, 131.0, 130.6, 130.5, 128.5, 128.0, 127.3, 126.5, 121.1, 120.7, 120.5 (q, *J* = 255.5 Hz).

HRMS (ESI, m/z) calcd. for $C_{21}H_{14}F_3N_2O_2$ [M+H]⁺: 383.1007; found: 383.1014.



2'-(4-oxo-3,4-dihydroquinazolin-2-yl)-[1,1'-biphenyl]-4-carbonitrile (3aj):

Column chromatography (SiO₂, eluting with 5:1 hexane/ethyl acetate) afforded the desired product as a brown solid (53.3 mg, 55%).

¹H NMR (400 MHz, CDCl₃) δ 10.49 (s, 1H), 8.16 (dd, *J* = 8.0, 1.5 Hz, 1H), 7.84 (dd, *J* = 7.5, 1.6 Hz, 1H), 7.82 – 7.76 (m, 1H), 7.65 (td, *J* = 8.1, 7.6, 1.3 Hz, 2H), 7.59 (td, *J* = 7.5, 1.5 Hz, 1H), 7.54 – 7.48 (m, 4H), 7.45 – 7.41 (m, 2H).

 ^{13}C NMR (100 MHz, CDCl_3) δ 162.7, 152.9, 149.0, 144.6, 139.2, 135.2, 132.9, 132.3, 131.3, 130.9, 130.4, 129.9, 129.2, 128.0, 127.5, 126.4, 120.5, 118.6, 111.6.

HRMS (ESI, m/z) calcd. for $C_{21}H_{14}N_3O [M+H]^+$: 324.1137; found: 324.1124.



methyl 2'-(4-oxo-3,4-dihydroquinazolin-2-yl)-[1,1'-biphenyl]-4-carboxylate (3ak):

Column chromatography (SiO₂, eluting with 5:1 hexane/ethyl acetate) afforded the desired product as a brown solid (52.3 mg, 49%).

¹H NMR (400 MHz, CDCl₃) δ 9.63 (s, 1H), 8.17 (dd, *J* = 7.9, 1.5 Hz, 1H), 7.95 – 7.90 (m, 2H), 7.84 (dd, *J* = 7.7, 1.5 Hz, 1H), 7.81 – 7.75 (m, 1H), 7.73 (dd, *J* = 8.2, 1.3 Hz, 1H), 7.62 (td, *J* = 7.5, 1.5 Hz, 1H), 7.55 (td, *J* = 7.6, 1.4 Hz, 1H), 7.52 – 7.46 (m, 2H), 7.42 – 7.37 (m, 2H), 3.87 (s, 3H).

 ^{13}C NMR (100 MHz, CDCl_3) δ 166.7, 162.1, 153.3, 149.1, 144.1, 139.8, 135.0, 133.0, 131.2, 130.9, 130.4, 130.0, 129.6, 129.1, 128.7, 128.0, 127.3, 126.5, 120.7, 52.3.

HRMS (ESI, m/z) calcd. for $C_{22}H_{17}N_2O_3$ [M+H]⁺ : 357.1239; found: 357.1237.



2-(4'-acetyl-[1,1'-biphenyl]-2-yl)quinazolin-4(3H)-one (3al):

Column chromatography (SiO₂, eluting with 5:1 hexane/ethyl acetate) afforded the desired product as a brown solid (50 mg, 49%).

¹H NMR (400 MHz, $CDCl_3$) δ 9.97 (s, 1H), 8.16 (dd, J = 7.9, 1.5 Hz, 1H), 7.84 – 7.76 (m, 4H), 7.73 (dd, J = 8.3, 1.3 Hz, 1H), 7.61 (td, J = 7.5, 1.5 Hz, 1H), 7.56 – 7.47 (m, 3H), 7.44 – 7.38 (m, 2H), 2.52 (s, 3H).

 ^{13}C NMR (100 MHz, CDCl_3) δ 197.6, 162.3, 153.3, 149.1, 144.3, 139.7, 136.2, 135.0, 132.9, 131.2, 130.9, 130.5, 129.3, 128.7, 128.0, 127.3, 126.5, 120.7, 26.7.

HRMS (ESI, m/z) calcd. for $C_{22}H_{17}N_2O_2$ [M+H]⁺ : 341.1290; found: 341.1279.



2-(4'-nitro-[1,1'-biphenyl]-2-yl)quinazolin-4(3H)-one (3am):

Column chromatography (SiO₂, eluting with 5:1 hexane/ethyl acetate) afforded the desired product as a brown solid (70 mg, 68%).

¹H NMR (400 MHz, $CDCl_3$) δ 10.40 (s, 1H), 8.16 (dd, *J* = 7.9, 1.6 Hz, 1H), 8.12 – 8.07 (m, 2H), 7.83 (dd, *J* = 7.4, 1.6 Hz, 1H), 7.81 – 7.76 (m, 1H), 7.69 – 7.64 (m, 2H), 7.61 (td, *J* = 7.5, 1.5 Hz, 1H), 7.54 – 7.46 (m, 4H).

 ^{13}C NMR (100 MHz, CDCl₃) δ 163.0, 152.9, 149.0, 147.2, 146.7, 139.0, 135.3, 133.0, 131.3, 130.9, 130.4, 130.0, 129.3, 128.0, 127.5, 126.4, 123.7, 120.5.

HRMS (ESI, m/z) calcd. for $C_{20}H_{14}N_3O_3$ [M+H]⁺ : 344.1035; found: 344.1024.



2-(3'-(trifluoromethyl)-[1,1'-biphenyl]-2-yl)quinazolin-4(3H)-one (3an):

Column chromatography (SiO₂, eluting with 5:1 hexane/ethyl acetate) afforded the desired product as a brown solid (87.8 mg, 80%).

¹H NMR (400 MHz, CDCl₃) δ 10.54 (s, 1H), 8.14 (dd, *J* = 8.0, 1.5 Hz, 1H), 7.83 – 7.75 (m, 2H), 7.72 – 7.66 (m, 2H), 7.63 (td, *J* = 7.6, 1.4 Hz, 1H), 7.58 – 7.46 (m, 4H), 7.42 (d, *J* = 7.9 Hz, 1H), 7.27 (t, *J* = 7.8 Hz, 1H).

 ^{19}F NMR (376 MHz, CDCl₃) δ -62.72.

¹³C NMR (100 MHz, CDCl₃) δ 162.8, 153.3, 149.0, 140.4, 139.5, 135.0, 133.1, 132.4, 131.2, 130.9, 131.0 (q, J = 32 Hz), 130.3, 128.9, 128.7, 127.9, 127.3, 126.4, 126.1 (q, J = 3.7 Hz), 123.9 (q, J = 271 Hz), 124.5 (q, J = 3.7 Hz), 120.5.

HRMS (ESI, m/z) calcd. for $C_{21}H_{14}F_3N_2O \ [M+H]^+$: 367.1058; found: 367.1060.



2-(3'-bromo-[1,1'-biphenyl]-2-yl)quinazolin-4(3H)-one (3ao):

Column chromatography (SiO₂, eluting with 5:1 hexane/ethyl acetate) afforded the desired product as a brown solid (73.5 mg, 65%).

¹H NMR (600 MHz, CDCl₃) δ 10.19 (s, 1H), 8.18 (d, *J* = 7.8 Hz, 1H), 7.80 (dd, *J* = 15.4, 7.5 Hz, 2H), 7.75 (d, *J* = 8.1 Hz, 1H), 7.59 (t, *J* = 7.5 Hz, 1H), 7.56 (s, 1H), 7.50 (t, *J* = 7.4 Hz, 2H), 7.46 (d, *J* = 7.7 Hz, 1H), 7.37 (dd, *J* = 8.0, 1.9 Hz, 1H), 7.15 (d, *J* = 7.6 Hz, 1H), 7.04 (t, *J* = 7.8 Hz, 1H).

 ^{13}C NMR (100 MHz, CDCl_3) δ 162.5, 153.4, 149.1, 141.5, 139.3, 135.0, 132.8, 132.1, 131.2, 131.0, 130.9, 130.5, 130.0, 128.6, 127.9, 127.8, 127.3, 126.5, 122.8, 120.7.

HRMS (ESI, m/z) calcd. for $C_{20}H_{14}BrN_2O [M+H]^+$: 377.0290; found: 377.0289.



2-(3'-nitro-[1,1'-biphenyl]-2-yl)quinazolin-4(3H)-one (3ap):

Column chromatography (SiO₂, eluting with 5:1 hexane/ethyl acetate) afforded the desired product as a brown solid (62.7 mg, 61%).

¹H NMR (400 MHz, CDCl₃) δ 10.59 (s, 1H), 8.32 (t, *J* = 1.9 Hz, 1H), 8.15 (dd, *J* = 7.9, 1.5 Hz, 1H), 8.10 (dd, *J* = 8.1, 1.8 Hz, 1H), 7.83 (d, *J* = 7.4 Hz, 1H), 7.81 – 7.76 (m, 1H), 7.66 (t, *J* = 7.9 Hz, 2H), 7.62 – 7.53 (m, 3H), 7.51 (t, *J* = 7.5 Hz, 1H), 7.35 (t, *J* = 7.9 Hz, 1H).

 ^{13}C NMR (100 MHz, CDCl_3) δ 162.8, 152.8, 148.9, 148.3, 141.5, 138.7, 135.2, 135.2, 133.1, 131.4, 131.0, 130.4, 129.3, 129.1, 128.0, 127.5, 126.4, 124.3, 122.6, 120.5.

HRMS (ESI, m/z) calcd. for $C_{20}H_{14}N_3O_3$ [M+H]⁺ : 344.1035; found: 344.1029.



2-(2'-methoxy-[1,1'-biphenyl]-2-yl)quinazolin-4(3H)-one (3aq):

Column chromatography (SiO₂, eluting with 5:1 hexane/ethyl acetate) afforded the desired product as a brown solid (64 mg, 65%).

¹H NMR (400 MHz, CDCl₃) δ 9.35 (s, 1H), 8.18 (dt, *J* = 8.0, 1.1 Hz, 1H), 7.93 (dd, *J* = 7.7, 1.5 Hz, 1H), 7.74 (d, *J* = 1.1 Hz, 1H), 7.73 (t, *J* = 1.2 Hz, 1H), 7.58 (td, *J* = 7.5, 1.7 Hz, 1H), 7.53 (td, *J* = 7.5, 1.6 Hz, 1H), 7.46 – 7.41 (m, 1H), 7.40 – 7.32 (m, 2H), 7.23 (dd, *J* = 7.5, 1.8 Hz, 1H), 7.00 (td, *J* = 7.5, 1.0 Hz, 1H), 6.92 (dd, *J* = 8.4, 1.1 Hz, 1H), 3.67 (s, 3H).

¹³C NMR (100 MHz, CDCl₃) δ 161.5, 155.9, 153.8, 149.4, 137.1, 134.7, 133.7, 131.7, 131.3, 130.9, 130.3, 129.7, 128.4, 128.3, 127.9, 126.8, 126.5, 121.6, 120.9, 111.1, 55.5.

HRMS (ESI, m/z) calcd. for $C_{21}H_{17}N_2O_2$ [M+H]⁺ : 329.1290; found: 329.1277.



2-(2'-bromo-[1,1'-biphenyl]-2-yl)quinazolin-4(3H)-one (3ar):

Column chromatography (SiO₂, eluting with 5:1 hexane/ethyl acetate) afforded the desired product as a brown solid (38.5 mg, 34%).

¹H NMR (400 MHz, $CDCl_3$) δ 9.10 (s, 1H), 8.18 (dd, *J* = 7.9, 1.3 Hz, 1H), 7.98 (d, *J* = 4.9 Hz, 1H), 7.73 (t, *J* = 7.3 Hz, 1H), 7.68 – 7.58 (m, 4H), 7.44 (t, *J* = 7.4 Hz, 1H), 7.40 (dd, *J* = 6.5, 2.1 Hz, 1H), 7.37 – 7.29 (m, 2H), 7.22 (t, *J* = 7.3 Hz, 1H).

 ^{13}C NMR (100 MHz, CDCl_3) δ 161.6, 152.4, 149.0, 140.5, 139.9, 134.8, 133.2, 133.1, 131.5, 131.3, 130.9, 130.0, 129.7, 129.0, 128.0, 127.1, 126.5, 123.2, 120.8.

HRMS (ESI, m/z) calcd. for $C_{20}H_{14}BrN_2O [M+H]^+$: 377.0290; found: 377.0283.



2-(2'-nitro-[1,1'-biphenyl]-2-yl)quinazolin-4(3H)-one (3as):

Column chromatography (SiO₂, eluting with 5:1 hexane/ethyl acetate) afforded the desired product as a brown solid (18.5 mg, 18%).

¹H NMR (600 MHz, CDCl₃) δ 9.73 (s, 1H), 8.18 (dd, *J* = 7.9, 1.6 Hz, 1H), 8.02 – 7.94 (m, 1H), 7.89 (dd, *J* = 7.4, 1.6 Hz, 1H), 7.73 (t, *J* = 7.7 Hz, 1H), 7.64 (d, *J* = 8.1 Hz, 1H), 7.62-7.55 (m, 2H), 7.50 – 7.47 (m, 2H), 7.45 (t, *J* = 7.5 Hz, 1H), 7.30 – 7.25 (m, 2H).

 ^{13}C NMR (100 MHz, CDCl_3) δ 161.8, 152.2, 149.6, 148.8, 137.0, 135.0, 134.9, 133.0, 132.7, 132.0, 131.0, 129.7, 129.5, 129.2, 127.9, 127.2, 126.5, 124.2, 120.9.

HRMS (ESI, m/z) calcd. for $C_{20}H_{14}N_3O_3$ [M+H]⁺ : 344.1035; found: 344.1041.



2-(4'-bromo-5-methyl-[1,1'-biphenyl]-2-yl)quinazolin-4(3H)-one (4bb):

Column chromatography (SiO₂, eluting with 5:1 hexane/ethyl acetate) afforded the desired product as a brown solid (91.5 mg, 78%).

¹H NMR (400 MHz, $CDCI_3$) δ 9.71 (s, 1H), 8.18 (dd, *J* = 7.9, 1.5 Hz, 1H), 7.82 - 7.76 (m, 1H), 7.76 - 7.70 (m, 2H), 7.52 - 7.45 (m, 1H), 7.37 - 7.33 (m, 2H), 7.29 - 7.26 (m, 1H), 7.24 (s, 1H), 7.18 - 7.14 (m, 2H), 2.44 (s, 3H).

 ^{13}C NMR (100 MHz, CDCl₃) δ 162.2, 153.5, 149.2, 141.5, 139.3, 138.5, 134.9, 131.9, 131.6, 130.7, 130.6, 123.0, 129.1, 127.9, 127.1, 126.5, 122.4, 120.7, 21.6.

HRMS (ESI, m/z) calcd. for $C_{21}H_{16}BrN_2O [M+H]^+$: 391.0446; found: 391.0445.



2-(4'-bromo-5-methoxy-[1,1'-biphenyl]-2-yl)quinazolin-4(3H)-one (4cb):

Column chromatography (SiO₂, eluting with 5:1 hexane/ethyl acetate) afforded the desired product as a brown solid (91.6 mg, 75%).

¹H NMR (400 MHz, CDCl₃) δ 9.52 (s, 1H), 8.18 (dd, *J* = 7.9, 1.5 Hz, 1H), 7.81 (d, *J* = 8.6 Hz, 1H), 7.79 – 7.71 (m, 2H), 7.50 – 7.45 (m, 1H), 7.41 – 7.36 (m, 2H), 7.22 – 7.16 (m, 2H), 7.01 (dd, *J* = 8.7, 2.6 Hz, 1H), 6.93 (d, *J* = 2.6 Hz, 1H), 3.88 (s, 3H).

 ^{13}C NMR (100 MHz, CDCl_3) δ 162.2, 161.6, 153.2, 149.3, 141.2, 138.3, 134.9, 132.4, 132.0, 130.6, 127.9, 127.0, 126.5, 125.3, 122.7, 120.6, 116.4, 113.7, 55.7.

HRMS (ESI, m/z) calcd. for $C_{21}H_{16}BrN_2O_2 [M+H]^+$: 407.0395; found: 407.0385.



2-(4'-bromo-6-methoxy-[1,1'-biphenyl]-2-yl)quinazolin-4(3H)-one (4db):

Column chromatography (SiO₂, eluting with 5:1 hexane/ethyl acetate) afforded the desired product as a brown solid (62.1 mg, 51%).

¹H NMR (600 MHz, CDCl₃) δ 9.17 (s, 1H), 8.21 (dd, *J* = 8.0, 1.4 Hz, 1H), 7.83 – 7.77 (m, 2H), 7.53 – 7.49 (m, 1H), 7.42 – 7.34 (m, 4H), 7.19 – 7.15 (m, 2H), 7.13 (dd, *J* = 8.6, 2.8 Hz, 1H), 3.91 (s, 3H).

¹³C NMR (100 MHz, CDCl₃) δ 161.6, 159.6, 153.5, 148.3, 137.8, 135.2, 132.3, 132.1, 131.8, 130.7, 127.7, 127.6, 126.7, 124.7, 122.3, 120.7, 118.1, 115.3, 55.9.

HRMS (ESI, m/z) calcd. for C₂₁H₁₆BrN₂O₂ [M+H]⁺ : 407.0395; found: 407.0383.



2-(4'-bromo-[1,1'-biphenyl]-2-yl)-6-methylquinazolin-4(3H)-one (4eb):

Column chromatography (SiO₂, eluting with 5:1 hexane/ethyl acetate) afforded the desired product as a brown solid (83.3 mg, 71%).

¹H NMR (400 MHz, CDCl₃) δ 10.46 (s, 1H), 7.91 (s, 1H), 7.74 (dd, *J* = 7.9, 1.5 Hz, 1H), 7.63 (d, *J* = 8.3 Hz, 1H), 7.59 (dd, *J* = 8.4, 2.0 Hz, 1H), 7.50 (td, *J* = 7.5, 1.4 Hz, 1H), 7.43 – 7.36 (m, 2H), 7.29 – 7.23 (m, 2H), 7.14 – 7.08 (m, 2H), 2.48 (s, 3H).

¹³C NMR (100 MHz, CDCl₃) δ 162.5, 152.7, 147.1, 139.5, 138.5, 137.5, 136.4, 132.8, 131.7, 131.0, 130.7, 130.7, 130.4, 128.3, 127.7, 125.8, 122.2, 120.4, 21.5.

HRMS (ESI, m/z) calcd. for $C_{21}H_{16}BrN_2O [M+H]^+$: 391.0446; found: 391.0433.



2-(4'-bromo-[1,1'-biphenyl]-2-yl)-6-methoxyquinazolin-4(3H)-one (4fb):

Column chromatography (SiO₂, eluting with 5:1 hexane/ethyl acetate) afforded the desired product as a brown solid (85.5 mg, 70%).

¹H NMR (600 MHz, $CDCl_3$) δ 9.21 (s, 1H), 7.83 (d, *J* = 7.6 Hz, 1H), 7.74 (d, *J* = 8.9 Hz, 1H), 7.58 (t, *J* = 7.5 Hz, 1H), 7.55 (d, *J* = 2.8 Hz, 1H), 7.51 (t, *J* = 7.7 Hz, 1H), 7.45 (d, *J* = 7.6 Hz, 1H), 7.37-7.43 (m, 3H), 7.19 (d, *J* = 8.1 Hz, 2H), 3.91 (s, 3H).

 ^{13}C NMR (100 MHz, CDCl_3) δ 161.6, 158.9, 151.1, 143.3, 139.4, 138.2, 132.5, 132.2, 131.5, 131.2, 130.9, 130.6, 129.4, 128.5, 125.3, 122.7, 121.5, 106.1, 56.0.

HRMS (ESI, m/z) calcd. for $C_{21}H_{16}BrN_2O_2$ [M+H]⁺ : 407.0395; found: 407.0386.



2-(4'-bromo-[1,1'-biphenyl]-2-yl)-8-methylquinazolin-4(3H)-one (4gb):

Column chromatography (SiO₂, eluting with 5:1 hexane/ethyl acetate) afforded the desired product as a brown solid (46.9 mg, 40%).

¹H NMR (400 MHz, CDCl₃) δ 9.15 (s, 1H), 8.06 (dd, *J* = 8.1, 1.6 Hz, 1H), 7.88 (dd, *J* = 7.5, 1.6 Hz, 1H), 7.63 - 7.58 (m, 2H), 7.55 (td, *J* = 7.5, 1.5 Hz, 1H), 7.49 - 7.42 (m, 3H), 7.37 (t, *J* = 7.6 Hz, 1H), 7.24 - 7.19 (m, 2H), 2.49 (s, 3H).

¹³C NMR (100 MHz, CDCl₃) δ 162.6, 151.4, 147.6, 140.0, 139.0, 136.7, 135.6, 132.9, 131.9, 131.1, 130.8, 130.6, 128.5, 126.8, 124.1, 122.3, 120.7, 17.6.

HRMS (ESI, m/z) calcd. for C₂₁H₁₆BrN₂O [M+H]⁺ : 391.0446; found: 391.0448.



2-(5-chloro-4'-methoxy-[1,1'-biphenyl]-2-yl)quinazolin-4(3H)-one (4hg):

Column chromatography (SiO₂, eluting with 5:1 hexane/ethyl acetate) afforded the desired product as a brown solid (41.4 mg, 38%).

¹H NMR (400 MHz, CDCl₃) δ 8.17 (dd, *J* = 7.3, 1.1 Hz, 1H), 7.89 – 7.78 (m, 3H), 7.55 – 7.50 (m, 1H), 7.44 (d, *J* = 2.1 Hz, 1H), 7.40 (dd, *J* = 8.3, 2.2 Hz, 1H), 7.23 – 7.15 (m, 2H), 6.80 – 6.73 (m, 2H), 3.74 (s, 3H).

 ^{13}C NMR (100 MHz, CDCl_3) δ 161.7, 160.0, 153.4, 148.1, 142.1, 137.5, 135.3, 132.1, 130.9, 130.3, 130.1, 129.9, 127.8, 127.6, 127.4, 126.7, 120.6, 114.6, 55.4.

HRMS (ESI, m/z) calcd. for $C_{21}H_{16}CIN_2O_2$ [M+H]⁺ : 363.0900; found: 363.0891.



2-(4'-methoxy-5-(trifluoromethyl)-[1,1'-biphenyl]-2-yl)quinazolin-4(3H)-one (4ig):

Column chromatography (SiO₂, eluting with 5:1 hexane/ethyl acetate) afforded the desired product as a brown solid (41.6 mg, 35%).

¹H NMR (400 MHz, CDCl₃) δ 9.65 (s, 1H), 8.17 (d, *J* = 7.7 Hz, 1H), 7.97 (d, *J* = 8.5 Hz, 1H), 7.86 – 7.78 (m, 2H), 7.72 (d, *J* = 4.3 Hz, 2H), 7.55 – 7.50 (m, 1H), 7.28 – 7.20 (m, 2H), 6.85 – 6.75 (m, 2H), 3.75 (s, 3H).

 ^{19}F NMR (376 MHz, CDCl₃) δ -62.76.

¹³C NMR (100 MHz, CDCl₃) δ 162.1, 160.1, 152.7, 149.0, 141.2, 135.7, 135.1, 133.0 (q, J = 32.8 Hz), 131.3, 130.3, 130.0, 128.1, 127.8 (q, J = 3.7 Hz), 127.5, 126.6, 124.3 (q, J = 3.7 Hz), 123.8 (q, J = 271.2 Hz), 120.9, 114.6, 55.3.

HRMS (ESI, m/z) calcd. for $C_{22}H_{16}F_3N_2O_2$ [M+H]⁺ : 397.1164; found: 397.1165.



3-(4'-methoxy-[1,1'-biphenyl]-2-yl)isoquinolin-1(2H)-one (8a):

Column chromatography (SiO₂, eluting with 4:1 hexane/ethyl acetate) afforded the desired product as a brown solid (27.5 mg, 28%).

¹H NMR (600 MHz, $CDCl_3$) δ 8.46 (s, 1H), 8.31 (d, J = 8.0 Hz, 1H), 7.64 (t, J = 7.5 Hz, 1H), 7.55 (d, J = 7.6 Hz, 1H), 7.53 - 7.49 (m, 2H), 7.47 - 7.41 (m, 3H), 7.24 (d, J = 8.2 Hz, 2H), 6.81 (d, J = 8.3 Hz, 2H), 6.52 (s, 1H), 3.76 (s, 3H).

 ^{13}C NMR (100 MHz, CDCl_3) δ 159.4, 140.2, 140.1, 138.3, 133.3, 132.9, 131.8, 131.2, 130.3, 130.2, 130.0, 127.7, 127.6, 126.8, 126.5, 114.3, 107.2, 55.3.

HRMS (ESI, m/z) calcd. for $C_{22}H_{18}NO_2 [M+H]^+$: 328.1338 ; found: 328.1330.



3-(4,4"-dimethoxy-[1,1':3',1"-terphenyl]-2'-yl)isoquinolin-1(2H)-one (8b):

Column chromatography (SiO₂, eluting with 4:1 hexane/ethyl acetate) afforded the desired product as a brown solid (23.4 mg, 18%).

¹H NMR (600 MHz, CDCl₃) δ 8.27 (s, 1H), 8.23 (d, *J* = 8.0 Hz, 1H), 7.52 (q, *J* = 7.1 Hz, 2H), 7.41 (d, *J* = 7.7 Hz, 2H), 7.38 (t, *J* = 7.8 Hz, 1H), 7.25 (d, *J* = 8.0 Hz, 1H), 7.17 (d, *J* = 8.3 Hz, 4H), 6.74 (d, *J* = 8.4 Hz, 4H), 6.09 (s, 1H), 3.72 (s, 6H).

 ^{13}C NMR (100 MHz, CDCl_3) δ 158.9, 142.2, 137.8, 137.7, 132.8, 132.6, 131.8, 130.0, 129.8, 129.6, 127.4, 126.6, 126.4, 113.9, 110.4, 55.3.

HRMS (ESI, m/z) calcd. for $C_{29}H_{24}NO_3$ [M+H]⁺ : 434.1756; found: 434.1751.



2-(4'-bromo-3-methyl-[1,1'-biphenyl]-2-yl)quinazolin-4(3H)-one- Detected by LC-MS.

HRMS (ESI, m/z) calcd. for C₂₁H₁₆BrN₂O [M+H]⁺ : 391.0446; found: 391.0457.



4-chloro-2-(4'-methyl-[1,1'-biphenyl]-2-yl)quinazoline (5af):

Column chromatography (SiO₂, eluting with 19:1 hexane/ethyl acetate) afforded the desired product as a white solid (52 mg, 80%).

¹H NMR (400 MHz, $CDCl_3$) δ 8.20 (d, J = 8.2 Hz, 1H), 7.98 – 7.85 (m, 3H), 7.71-7.63 (m, 1H), 7.57 – 7.45 (m, 3H), 7.09 (d, J = 8.1 Hz, 2H), 7.02 (d, J = 7.8 Hz, 2H), 2.30 (s, 3H).

 ^{13}C NMR (100 MHz, CDCl_3) δ 163.3, 161.9, 151.4, 142.2, 138.7, 137.2, 136.3, 134.9, 131.0, 131.0, 129.9, 129.2, 128.9, 128.8, 128.6, 127.4, 125.8, 121.9, 21.2.

HRMS (ESI, m/z) calcd. for $C_{21}H_{16}CIN_2 [M+H]^+$: 331.1002; found: 331.0992.



2-(3'-fluoro-4'-methoxy-[1,1'-biphenyl]-2-yl)quinazolin-4(3H)-one (3au'):

Column chromatography (SiO₂, eluting with 19:1 hexane/ethyl acetate) afforded the desired product as a white solid (67 mg, 64%).

¹H NMR (600 MHz, CDCl₃) δ 9.94 (s, 1H), 8.17 (d, *J* = 7.8 Hz, 1H), 7.82 – 7.76 (m, 3H), 7.55 – 7.48 (m, 2H), 7.42 (t, *J* = 7.0 Hz, 2H), 7.07 (dd, *J* = 12.0, 2.1 Hz, 1H), 6.76 (t, *J* = 8.5 Hz, 1H), 3.79 (s, 3H).

¹⁹F NMR (376 MHz, CDCl₃) δ -134.16.

¹³C NMR (100 MHz, CDCl₃) δ 152.2 (d, *J* = 247.2 Hz), 147.5 (d, *J* = 10.6 Hz), 132.1 (d, *J* = 6.6 Hz), 125.1 (d, *J* = 3.4 Hz), 116.9 (d, *J* = 19.1 Hz), 113.4 (d, *J* = 2.2 Hz).

HRMS (ESI, m/z) calcd. for C₂₁H₁₆FN₂O₂ [M+H]⁺ : 347.1196; found: 347.1124.

Nuisance effect and C-H arylation for 4-fluoro aryl diazonium salt:







Figure 10: MS analysis of the arylation reaction of 4-fluoro aryl diazonium salt with 2-phenyl quinazolinone.

Crystal structure of 3aj:

The crystals of **3aj** were grown in dichloromethane-hexane solvent system. The crystal data was collected in X-ray spectroscopy (Bruker Kappa Apex-2, CCD Area Detector), and the data was analyzed using OLEX2 software. The structure is given below. The corresponding cif file has been uploaded separately as supporting information.



Thermal ellipsoid plot of **3aj**. Ellipsoids are represented with 50% probability. X-ray determined molecular structure of **3aj**, **CCDC**: **2333220**

Identification code	SHM_305_0m_a
Empirical formula	C ₂₁ H ₁₃ N ₃ O
Formula weight	323.34
Temperature/K	122
Crystal system	monoclinic
Space group	P21/c
a/Å	4.7332(2)
b/Å	20.9652(8)
c/Å	16.2410(6)
α/°	90
β/°	94.249(10)
γ/°	90
Volume/ų	1607.21(11)
Z	4
$\rho_{calc}g/cm^3$	1.336
µ/mm⁻¹	0.677
F(000)	672.0
Crystal size/mm ³	0.32 x 0.12x 0.1

Radiation	CuK _α (λ = 1.54178)
20 range for data collection/°	8.434 to 133.312
Index ranges	-5 ≤ h ≤ 5, -24 ≤ k ≤ 24, -19 ≤ l ≤ 19
Reflections collected	22992
Independent reflections	2803 [R _{int} = 0.0597, R _{sigma} = 0.0358]
Data/restraints/parameters	2803/0/230
Goodness-of-fit on F ²	1.065
Final R indexes [I>=2σ (I)]	$R_1 = 0.0451$, $wR_2 = 0.1200$
Final R indexes [all data]	$R_1 = 0.0465$, $wR_2 = 0.12014$
Largest diff. peak/hole / e Å ⁻³	0.18/-0.24

Crystal structure of 3au':

The crystals of **3au'** were grown in chloroform-hexane solvent system. The crystal data was collected in X-ray spectroscopy (Bruker Kappa Apex-2, CCD Area Detector), and the data was analyzed using OLEX2 software. The structure is given below. The corresponding cif file has been uploaded separately as supporting information.



Thermal ellipsoid plot of **3au'**. Ellipsoids are represented with 50% probability. X-ray determined molecular structure of **3au'**, **CCDC: 2353282**

Identification code	SHM_420_0m_a
Empirical formula	$C_{84}H_{60}F_4N_8O_8$
Formula weight	1385.40
Temperature/K	100.00
Crystal system	monoclinic
Space group	P21/c
a/Å	7.4997(6)

b/Å	13.6212(11)
c/Å	16.1797(12)
α/°	90
β/°	93.812(4)
γ/°	90
Volume/ų	1649.2(2)
Z	1
$\rho_{calc} g/cm^3$	1.395
µ/mm ⁻¹	0.812
F(000)	720.0
Crystal size/mm ³	$0.2 \times 0.1 \times 0.09$
Radiation	CuK _α (λ = 1.54178)
20 range for data collection/°	8.494 to 137.322
Index ranges	-8 ≤ h ≤ 8, -15 ≤ k ≤ 16, -19 ≤ l ≤ 19
Reflections collected	24330
Independent reflections	2914 [R _{int} = 0.0776, R _{sigma} = 0.0433]
Data/restraints/parameters	2914/0/241
Goodness-of-fit on F ²	1.071
Final R indexes [I>=2σ (I)]	$R_1 = 0.0682$, $wR_2 = 0.1471$
Final R indexes [all data]	$R_1 = 0.0729$, w $R_2 = 0.1533$
Largest diff. peak/hole / e Å- ³	0.25/-0.28

References:

- 1. R. Cheng, T. Guo, D. Zhang-Negrerie, Y. Du and K. Zhao, *Synthesis*, 2013, **45**, 2998-3006.
- 2. N. Y. Kim and C.-H. Cheon, *Tetrahedron Lett.*, 2014, **55**, 2340-2344.
- 3. X. Tian, L. Song, E. Li, Q. Wang, W. Yu and J. Chang, *RSC Adv.*, 2015, **5**, 62194-62201.
- 4. Y. Shi, X. Zhu, H. Mao, H. Hu, C. Zhu and Y. Cheng, *Chem. Eur. J.*, 2013, **19**, 11553-11557.
- 5. J. Wu, Y. Gu, X. Leng and Q. Shen, *Angew. Chem. Int. Ed.*, 2015, **54**, 7648-7652.
- 6. L. J. Goossen, C. Linder, N. Rodríguez and P. P. Lange, *Chem. Eur. J.*, 2009, **15**, 9336-9349.
- 7. R. Dey, N. Mukherjee, S. Ahammed and B. C. Ranu, *Chem. Commun.*, 2012, **48**, 7982-7984.
- 8. A. Polley, K. Varalaxmi and R. Jana, *ACS Omega*, 2018, **3**, 14503-14516.
- 9. S. Witzel, M. Hoffmann, M. Rudolph, M. Kerscher, P. Comba, A. Dreuw and A. S. K. Hashmi, *Cell Rep. Phys. Sci.*, 2021, **2**, 100325.

NMR spectra



120 110 f1 (ppm) 220 210 200







-111.486 -111.515 -111.541 -129.469 -129.491 -129.546 -129.569 -129.569





110 100 f1 (ppm)





36










100 80 60 40 20 0 -20 -40 -60 -80 -100 -120 -140 -160 -180 -200 -220 -240 -260 -280 -300 f1 (ppm)











SHM-332 single pulse decoupled gated NOE 

100 80 60 40 20 0 -20 -40 -60 -80 -100 -120 -140 -160 -180 -200 -220 -240 -260 -280 -300 f1 (ppm)



SHM-333 single pulse decoupled gated NOE



100 80 60 40 20 0 -20 -40 -60 -80 -100 -120 -140 -160 -180 -200 -220 -240 -260 -280 -300 f1 (ppm)

---57.705





f1 (ppm)



SHM-302 839 5712 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512 772 8512









SHM-356 single pulse decoupled gated NOE 

100 80 60 40 20 0 -20 -40 -60 -80 -100 -120 -140 -160 -180 -200 -220 -240 -260 -280 -300 f1 (ppm)







110 100 f1 (ppm)

SHM-377 single_pulse

f1 (ppm)

f1 (ppm)

f1 (ppm)

SHM-502 single_pulse

8.183 8.162 8.162 8.162 8.162 8.162 8.163 8.163 8.163 8.163 8.163 8.163 8.163 8.163 8.163 8.163 8.163 8.163 8.163 8.163 8.163 8.163 8.163 8.164 8.173 8.164 8.173 8.164 8.173 8.164 8.173 8.164 8.173 8.164 8.173 8.164 8.174 8.174 8.174 8.174 8.174 8.174 8.174 8.174 8.174 8.174 8.174 8.174 8.174 8.174 8.174 8.174 8.174 8.174 8.174 8.174 8.174 8.174 8.174 8.174 8.174 8.174 8.174 8.174 8.174 8.174 8.174 8.174 8.174 8.174 8.174 8.174 8.174 8.174 8.174 8.174 8.174 8.174 8.174 8.174 8.174 8.175 8.175 8.175 8.175 8.175 8.175 8.175 8.175 8.175 8.175 8.175 8.175 8.175 8.175 8.175 8.175 8.175 8.175 8.175 8.175 8.175 8.175 8.175 8.175 8.175 8.175

SHM-492 single pulse decoupled gated NOE

-5 -10 -15 -20 -25 -30 -35 -40 -45 -50 -55 -60 -65 -70 -75 -80 -85 -90 -95 -100 -105 -110 -115 -120 -125 -130 -135 -140 -145 -150 -15 f1 (ppm)

SHM-420 1D 19F experiment

--115 -120 f1 (ppm) -75 -80 -85 -90 -95 -100 -105 -125 -145 -150 -155 -110 -130 -135 -140 -160

110 100 f1 (ppm) 1.

